8 news items
HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $9 Price Target
OVID
16 May 24
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ovid Therapeutics (NASDAQ:OVID) with a Buy and maintains $9 price target.
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
OVID
14 May 24
findings for our ROCK2 inhibition program and are planning to launch our Phase 2 study later this year, targeting cerebral cavernous malformations
Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics
OVID
7 May 24
0
Providing deeper insights, analysts have established 12-month price targets, indicating an average target
Citigroup Maintains Neutral on Ovid Therapeutics, Lowers Price Target to $3.5
OVID
7 May 24
Citigroup analyst Yigal Nochomovitz maintains Ovid Therapeutics (NASDAQ:OVID) with a Neutral and lowers the price target from $4 to $3.5.
B. Riley Securities Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $9
OVID
30 Apr 24
B. Riley Securities analyst Kalpit Patel initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $9.
yvhz6emhfzt2vhtbuny3029utbbhkuisto2y4cqtjy3x961krqhvxv4zye5y
OVID
29 Apr 24
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $9.
s3v5gc9
OVID
5 Apr 24
Wedbush analyst Laura Chico initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Price Target of $8.
4bo47o5yiue0aud2usapf2k62x7swc1n2o
OVID
8 Mar 24
, which includes surrogate biomarkers to measure target engagement and clinical efficacy. No safety signals were seen in single-ascending dose cohorts
- Prev
- 1
- Next